Tyra Biosciences, Inc.
NASDAQ:TYRA · NASDAQ Global Select
-$0.72 today
Vol 1.71M · Avg 0.96M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:TYRA · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$131.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.18, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $102.9M +28.5% | $80.1M +28.1% | $62.5M +45.4% | $43.0M +108.4% | $20.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $29.8M +23.8% | $24.1M +38.3% | $17.4M +9.5% | $15.9M +181.7% | $5.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $132.8M +27.4% | $104.2M +30.3% | $79.9M +35.7% | $58.9M +124.2% | $26.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $546.0K +5.2% | $519.0K +45.4% | $357.0K +20.6% | $296.0K +111.4% | $140.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$119.4M -38.9% | -$86.0M -25.0% | -$68.8M -25.0% | -$55.0M -110.4% | -$26.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$132.8M -27.4% | -$104.2M -30.3% | -$79.9M -35.7% | -$58.9M -124.2% | -$26.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $12.8M -27.6% | $17.7M +63.7% | $10.8M +196.0% | $3.7M +27992.3% | $13.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $12.8M -27.6% | $17.7M +63.7% | $10.8M +200.1% | $3.6M +60133.3% | -$6.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$119.9M -38.7% | -$86.5M -25.1% | -$69.1M -25.0% | -$55.3M -110.4% | -$26.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$119.9M -38.7% | -$86.5M -25.1% | -$69.1M -25.0% | -$55.3M -110.4% | -$26.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 -33.1% | -$2 +6.8% | -$2 -31.7% | -$1 -95.2% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 -33.1% | -$2 +6.8% | -$2 -31.7% | -$1 -95.2% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $59.6M +4.2% | $57.2M +34.0% | $42.7M +2.0% | $41.9M +1.1% | $41.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $59.6M +4.2% | $57.2M +34.0% | $42.7M +2.0% | $41.9M +1.1% | $41.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Nanobiotix S.A.
NASDAQ:NBTX
$1.79B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B
Savara Inc.
NASDAQ:SVRA
$1.11B
Kura Oncology, Inc.
NASDAQ:KURA
$852.23M
Geron Corporation
NASDAQ:GERN
$801.90M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$737.70M
Prime Medicine, Inc.
NASDAQ:PRME
$565.31M
Rezolute, Inc.
NASDAQ:RZLT
$494.46M
ProKidney Corp.
NASDAQ:PROK
$263.08M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TYRA generate?
Tyra Biosciences, Inc. (TYRA) reported $0.00 of revenue in fiscal 2025.
Is TYRA profitable?
Tyra Biosciences, Inc. (TYRA) reported -$119,947,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.